Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754707 | 0.88 | MAPT (0.54) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL25754703 | 0.88 | CYP19A1 (0.44) | KMT2AMEN1MAPTTBXA2RALDH1A1 | |
| SCHEMBL23833760 | 0.85 | MEN1 (0.48) | KMT2AMEN1MAPTLMNATBXA2R | |
| SCHEMBL25754705 | 0.85 | IDH1 (0.49) | KMT2AMEN1MAPTCA1CA2 | |
| SCHEMBL25754750 | 0.83 | MEN1 (0.51) | KMT2AMEN1MAPTLMNARAB9A | |
| SCHEMBL25754766 | 0.82 | SMN1; SMN2 (0.53) | KMT2AMEN1MAPTLMNATBXA2R | |
| SCHEMBL25754764 | 0.81 | ALPL (0.44) | KMT2AMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL25754679 | 0.81 | SMN1; SMN2 (0.64) | KMT2AMEN1LMNATBXA2RALDH1A1 | |
| SCHEMBL2243891 | 0.78 | ALPL (0.66) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL23199894 | 0.78 | HTT (0.46) | KMT2AMEN1MAPTLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | KMT2A 4864/4885MEN1 3902/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.